Eight US IPOs raised $3.3 billion this week, including four Chinese deals and three biotechs. iQIYI raised $2.3 billion, making it the largest Chinese IPO...read more
Unum Therapeutics, which is developing antibody-coupled T-cell receptor immunotherapies for cancers, raised $69 million by offering 5.77 million shares at $12, the low end of the range of $12 to $14. At pricing, it commands a fully diluted market value of $380...read more
Eight companies aim to raise a combined $3.5 billion in the short holiday week. Four Chinese IPOs lead the way, headlined by iQIYI (IQ), planning to raise over $2 billion in the largest Chinese offering since Alibaba in 2014. It is joined by...read more
Unum Therapeutics, which is developing antibody-coupled T cell immunotherapies for cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14....read more
US IPO Weekly Recap: 8-IPO week caps record 1Q with a flurry of Chinese deals
Eight US IPOs raised $3.3 billion this week, including four Chinese deals and three biotechs. iQIYI raised $2.3 billion, making it the largest Chinese IPO...read more
Immuno-oncology biotech Unum Therapeutics prices $69 million IPO at $12 low end
Unum Therapeutics, which is developing antibody-coupled T-cell receptor immunotherapies for cancers, raised $69 million by offering 5.77 million shares at $12, the low end of the range of $12 to $14. At pricing, it commands a fully diluted market value of $380...read more
US IPO Week Ahead: Largest Chinese deal since Alibaba leads 8-IPO week
Eight companies aim to raise a combined $3.5 billion in the short holiday week. Four Chinese IPOs lead the way, headlined by iQIYI (IQ), planning to raise over $2 billion in the largest Chinese offering since Alibaba in 2014. It is joined by...read more
Cancer immunotherapy biotech Unum Therapeutics sets terms for $75 million IPO
Unum Therapeutics, which is developing antibody-coupled T cell immunotherapies for cancers, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14....read more